Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4924955

CC(=O)c1ccc(-c2nnc(-c3cccnc3)o2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.59
RAB9A P51151 6/20 0.56
KDM4E B2RXH2 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
CA2 P00918 1/20 0.50
ATR Q13535 2/20 0.49
LMNA P02545 1/20 0.47
HSD17B10 Q99714 2/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.46
PKM P14618 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277474 0.91 NPC1 (0.66) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL4927459 0.88 NPC1 (0.74) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3625741 0.86 NPC1 (0.63) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3631758 0.86 NPC1 (0.63) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3633881 0.85 NPC1 (0.66) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3631429 0.85 NPC1 (0.61) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3625608 0.85 NPC1 (0.74) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL4921697 0.85 NPC1 (0.82) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3634033 0.85 NPC1 (0.61) NPC1RAB9AKDM4ESMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL3627900 0.85 NPC1 (0.59) NPC1RAB9AKDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255203-A1 HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE ABBOTT LABORATORIES (US) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255203-A1 HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE CYP11B2, AADAC, CYP11B1 NPC1 473/4885RAB9A 3859/4885KDM4E 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.